Aimed Bio (0009K0) stock
KOSDAQ · Biotechnology
As of the Nov 16 regular-session close (Korea)
Events and reference metrics · 1
- Market cap
- KRW 1.2 trillion
- As of Nov 13, 2026
- P/E
- 237.46x
- Trailing twelve months
- P/B
- 5.83x
- Latest reported equity
- P/S
- 25.23x
- Trailing twelve months
- ROE
- 2.5%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- KRW 1.2 trillion
- As of Nov 13, 2026
- P/E
- 237.46x
- Trailing twelve months
- P/B
- 5.83x
- Latest reported equity
- P/S
- 25.23x
- Trailing twelve months
- ROE
- 2.5%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
237.46x
P/B
5.83x
P/S
25.23x
Earnings and dividend metrics▾
Earnings
EPS
KRW 77
Earnings per share
BPS
KRW 3,139
Book value per share
ROE
2.5%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 77 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 3,139 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 2.5%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 12, 2026 | KRW 20.2 billion | KRW 8.5 billion | KRW 10.9 billion | — |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 8.5 billion | -KRW 4 billion | -KRW 2 billion | — |
| Q4 2025Consolidated · Filed Mar 19, 2026 | KRW 38 billion | KRW 25.5 billion | KRW 34.9 billion | — |
| 9M 2025Consolidated · Filed Dec 10, 2025 | KRW 9.3 billion | -KRW 4.8 billion | -KRW 29.9 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 19, 2026 | KRW 47.3 billion | KRW 20.8 billion | KRW 5 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Year-to-date rows are cumulative from the start of the fiscal year.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 11.39%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 660 million
- Previous 20-day average 7.20%
- Net short position
- 145,854 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 2,714,128 shares
- As of Nov 13, 2026 · 4.17% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 11.39% | KRW 660 million |
| Nov 12, 2026 | 6.03% | KRW 150 million |
| Nov 11, 2026 | 3.46% | KRW 160 million |
| Nov 10, 2026 | 7.61% | KRW 280 million |
| Nov 9, 2026 | 11.51% | KRW 370 million |
| Nov 6, 2026 | 6.67% | KRW 270 million |
| Nov 5, 2026 | 10.42% | KRW 500 million |
| Nov 4, 2026 | 6.91% | KRW 360 million |
| Nov 3, 2026 | 11.87% | KRW 360 million |
| Nov 2, 2026 | 2.02% | KRW 50 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Report on Major Holdings of Shares (Short Form)Nov 16, 2026 · Major Holding ReportEnglish
- Technology or Regulatory ApprovalOct 27, 2026English
- Technology or Regulatory Approval(Korean)Sep 22, 2026
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Sep 18, 2026 · Insider Ownership Report
- Technology or Regulatory Approval(Korean)Sep 2, 2026
- Technology or Regulatory Approval(Korean)Aug 21, 2026
- Technology or Regulatory Approval(Korean)Aug 18, 2026
- Technology or Regulatory Approval(Korean)Aug 10, 2026
Filings with a published English version open in English; the rest link to the Korean original.
Aimed Bio (0009K0) stock information
KOSDAQ
Aimed Bio (0009K0) is listed on KOSDAQ. Its market capitalization is about KRW 1.2 trillion. On trailing-twelve-month earnings the P/E ratio is 237.46, and the P/B ratio is 5.83. Return on equity is 2.5%. These figures are computed in-house from official filings and are reference information only.
Aimed Bio — frequently asked questions
- What is the P/E ratio of Aimed Bio (0009K0)?
- On a trailing-twelve-month basis, 0009K0 trades at a P/E ratio of 237.46. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Aimed Bio?
- 0009K0 has a market capitalization of about KRW 1.2 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.